Significance of Efficacy Results in a Randomized Clinical Trial—Reply

In Reply On behalf of my coauthors, I am writing to reply to a reader's query regarding the statistics of the primary efficacy end point in our article, "Safety and Efficacy of Anakinra in Severe Hidradenitis Suppurativa: A Randomized Clinical Trial," published online on November 18, 2015, and in the January 2016 issue of JAMA Dermatology. We are grateful to Dr Su for his inquiry.

http://ift.tt/2vn1ucV